In contrast, both sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like-peptide-1 receptor (GLP-1-R) agonists reduce the risk of all-cause mortality, cardiovascular mortality, and kidney failure [5]. The gene discussed is GLP1R; the disease is kidney failure.